Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1522 9645 "

Sökning: L773:1522 9645

Sortera/gruppera träfflistan
  • Aavik, Einari, et al. (författare)
  • Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster
  • 2015
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 36:16, s. 993-U23
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims Genetics can explain just above 10% of the observed heritability in cardiovascular diseases. Epigenetics is about to provide some further explanations, but the information needed for that is in the accumulation phase. Genome-wide DNA methylation analysis has revealed thousands of genes, which are epigenetically differentially regulated in atherosclerotic plaques. Our results point to an additional level of complexity that needs to be integrated into the aetiology of atherogenesis.We conducted a genome-wide analysis to identify differentially methylated genes in atherosclerotic lesions. Methods DNA methylation at promoters, exons and introns was identified by massive parallel sequencing. Gene expression was analysed by microarrays, qPCR, immunohistochemistry and western blots. Results Globally, hypomethylation of chromosomal DNA predominates in atherosclerotic plaques and two-thirds of genes showing over 2.5-fold differential in DNA methylation are up-regulated in comparison to healthy mammary arteries. The imprinted chromatin locus 14q32 was identified for the first time as an extensively hypomethylated area in atherosclerosis with highly induced expression of miR127, -136, -410, -431, -432, -433 and capillary formation-associated gene RTL1. The top 100 list of hypomethylated promoters exhibited over 1000-fold enrichment for miRNAs, many of which mapped to locus 14q32. Unexpectedly, also gene body hypermethylation was found to correlate with stimulated mRNA expression. Conclusion Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
  • Abraham, William T, et al. (författare)
  • Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
  • 2021
  • Ingår i: European heart journal. - 1522-9645. ; 42:6, s. 700-710
  • Tidskriftsartikel (refereegranskat)abstract
    • The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF).HF patients with reduced EF (HFrEF) (≤40%,N = 312, EMPERIAL-Reduced) or preserved EF (>40%,N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were -4.0 m (-16.0, 6.0;P = 0.42) and 4.0 m (-5.0, 13.0;P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported.The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.
  • Abrahamsson, Putte, 1965, et al. (författare)
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure
  • 2009
  • Ingår i: Eur Heart J. - 1522-9645. ; 30:3, s. 338-45
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: We explored the impact of having a hospital admission for an acute coronary syndrome (ACS) on the subsequent prognosis among patients with chronic heart failure (CHF). METHODS AND RESULTS: A total of 7599 patients with CHF, New York Heart Association Classes II-IV, were randomly assigned to candesartan or placebo. We assessed the risk of death after a first ACS using time-updated Cox proportional hazard models adjusted for baseline predictors. During a mean follow-up of 3.3 years, 1174 patients experienced at least one ACS. Myocardial infarction (MI) was the first ACS in 442 subjects and unstable angina (UA) in 732. After these events, 219 (49.5%) and 167 (22.8%) patients died during follow-up. The early risk of death was more pronounced after MI: 30.2% died within 30 days compared with 3.6% after UA. After an ACS event, the risk of death declined steadily over time, although 18 months after an MI the risk was still twice that of patients without an ACS. CONCLUSION: Patients with CHF, who develop an ACS, have markedly increased subsequent mortality, particularly in the early phase after an MI.
  • Aburawi, Elhadi, et al. (författare)
  • Relation of aortic root dilatation and age in Marfan's syndrome
  • 2007
  • Ingår i: European Heart Journal. - : Oxford University Press. - 1522-9645. ; 28:3, s. 376-379
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims The main aim of this study was to describe the age at which pathological aortic root dilation occurs in patients with Marfan's syndrome (MFS). Methods and results A total of 160 patients with MFS attending a regional cardiac centre were reviewed retrospectively. Dilation of the ascending aorta was diagnosed by comparing the maximum aortic sinus measurement with control data from the literature. We employed a Kaplan-Meier survival curve to estimate the age at which dilatation occurs. The mean age of the total group at presentation was 15.5 years (range 1.5-40 years). Skeletal abnormalities were present in 95%. Eye involvement was found in 18%. In the 115/160 patients with an abnormal aortic root, 78/115 (68%) developed aortic root dilatation before 19 years of age. From the Kaplan-Meier curve, it can be estimated that about 35% of the patients have aortic root dilatation already at the age of 5 years and 70% before the age of 20 years, and at least 80% by 40 years. There were 31 patients with normal aortic root when first seen but 24/31 (77%) developed aortic root dilatation before the age of 19 years and 7/31 (22.6%) after 19 years of age. Of those (seven patients) who developed new pathological aortic root dilatation after age 19 years, the age range was between 21 and 40 years with a mean of 27 years. Overall, 13 patients (8%) had surgery for aortic root replacement. Conclusion Aortic root dilatation develops early in MFS and was present in 35% by the age of 5 years and 68% by 19 years. Even though new aortic root dilation is relatively rare, it is not possible to safely discharge patients with MFS as about one-third of the patients in our series who developed new pathological aortic root dilation did so after the age of 19 years.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (930)
konferensbidrag (58)
forskningsöversikt (20)
annan publikation (3)
Typ av innehåll
refereegranskat (688)
övrigt vetenskapligt (323)
Wallentin, Lars (73)
Wallentin, Lars, 194 ... (54)
Jernberg, T (49)
Rydén, L. (44)
Erlinge, D. (35)
Agewall, S (34)
visa fler...
Herlitz, Johan (33)
James, Stefan (33)
Siegbahn, Agneta (30)
Cosentino, F (27)
Lindahl, Bertil (27)
Swedberg, Karl, 1944 (25)
Wallentin, L (25)
Swahn, Eva (24)
Granger, C. B. (23)
Blomström-Lundqvist, ... (22)
Söderberg, Stefan (22)
Linde, C (21)
Henein, Michael Y. (21)
Lindahl, B (21)
Held, Claes (21)
Roffi, M (20)
Bueno, H (20)
Zamorano, JL (20)
Aboyans, V (19)
Johansson, Bengt (19)
Alexander, J. H. (19)
Erlinge, David (18)
James, Stefan, 1964- (18)
Granger, Christopher ... (18)
Jaarsma, Tiny (17)
Windecker, Stephan (17)
Windecker, S (17)
James, Stefan K (17)
Lagerqvist, Bo (17)
Lopes, R. D. (17)
James, S. (16)
Dellborg, M (16)
Huber, Kurt (16)
Jernberg, Tomas (16)
Olsson, Bertil (16)
Hanna, M. (16)
Edner, M (15)
Husted, Steen (15)
Collet, JP (14)
Piepoli, MF (14)
Dahlström, Ulf (14)
Dahlstrom, U (14)
Landmesser, U. (14)
James, Stefan K, 196 ... (14)
visa färre...
Uppsala universitet (351)
Karolinska Institutet (285)
Umeå universitet (129)
Lunds universitet (114)
Göteborgs universitet (106)
Linköpings universitet (100)
visa fler...
Högskolan i Borås (35)
Kungliga Tekniska Högskolan (32)
Örebro universitet (22)
Linnéuniversitetet (9)
Jönköping University (7)
Högskolan i Halmstad (5)
Stockholms universitet (4)
Mälardalens högskola (4)
Mittuniversitetet (4)
Högskolan Väst (3)
Högskolan Dalarna (3)
Chalmers tekniska högskola (2)
Sveriges Lantbruksuniversitet (2)
Högskolan Kristianstad (1)
Malmö universitet (1)
Högskolan i Skövde (1)
Gymnastik- och idrottshögskolan (1)
Högskolan i Gävle (1)
visa färre...
Engelska (1011)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (537)
Teknik (7)
Samhällsvetenskap (3)
Lantbruksvetenskap (2)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy